Jasper Sets Sept 30 Vote on 1-for-15 to 1-for-35 Reverse Split and 185M Share Authorization Increase
JSPR has more than doubled off its 52-week low of $0.315 on light trading volume (0.2× avg).
Summary
Jasper Therapeutics filed its definitive proxy for a September 30 special meeting to vote on a reverse stock split (1-for-15 to 1-for-35) to regain Nasdaq compliance and an increase in authorized shares from 490M to 675M to satisfy the Kira merger agreement.
Key Events · Corporate Governance and Compliance · JSPR
-
Reverse Split Vote Set for Sept 30
Shareholders will vote on a reverse stock split at a ratio between 1-for-15 and 1-for-35, with the board having discretion to implement it by December 31, 2026. The stock closed at $0.6864 on September 3, 2026, below Nasdaq's $1.00 minimum bid price requirement.
-
Nasdaq Compliance Deadline Nov 30
Jasper received a Nasdaq deficiency notice on June 3, 2026, and has until November 30, 2026, to regain compliance with the $1.00 minimum bid price rule. The company has not yet regained compliance.
-
Authorized Share Increase to 675M
A separate proposal seeks to increase authorized common shares from 490M to 675M to permit conversion of the 9,555,390 shares of Preferred Stock issued in the Kira Pharmaceuticals merger and the $132M PIPE.
-
Merger Agreement Requirement
The Kira Pharmaceuticals merger agreement requires Jasper to seek stockholder approval for the authorized share increase to cover conversion of all Preferred Stock, including those issued in the PIPE.
Analysis · JSPR · Life Sciences
Jasper Therapeutics is asking shareholders to approve a reverse stock split of up to 1-for-35 to regain Nasdaq's $1.00 minimum bid price compliance before the November 30 deadline, and separately to increase authorized shares from 490M to 675M to satisfy the Kira Pharmaceuticals merger agreement. The stock closed at $0.6864 on September 3, 2026, well below the $1.00 threshold, and the company has not yet regained compliance. If the reverse split is approved, the board has discretion to implement it at any ratio between 1-for-15 and 1-for-35 by December 31, 2026. The authorized share increase is required to permit conversion of the 9.55M shares of Preferred Stock issued in the Kira merger and the $132M PIPE. Both proposals are independent, and the board does not currently intend to effect the authorized share increase if the reverse split is effected. The special meeting is set for September 30, 2026, with a record date of August 10, 2026.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.1M. The 52-week trading range was $0.32 to $2.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.